Unmasking the burden: Prevalence of painful diabetic peripheral neuropathy in type 2 diabetes mellitus
*Corresponding Author:
Received: 29-Nov-2023, Manuscript No. ajdm-24-125400; Editor assigned: 01-Dec-2023, Pre QC No. ajdm-24-125400 (PQ); Reviewed: 15-Dec-2023, QC No. ajdm-24-125400; Revised: 20-Dec-2023, Manuscript No. ajdm-24-125400 (R); Published: 27-Dec-2023, DOI: 10.54931/AJDM-31.6.1.
Introduction
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder affecting millions globally, with its complications extending far beyond elevated blood glucose levels. One of the debilitating complications is Painful Diabetic Peripheral Neuropathy (PDPN), a condition that significantly impacts the quality of life for those living with diabetes. Painful diabetic peripheral neuropathy is a type of nerve damage that occurs in individuals with diabetes. High blood sugar levels, combined with other metabolic factors, lead to nerve damage, resulting in pain and discomfort. PDPN commonly affects the extremities, particularly the feet, and can manifest as burning, tingling, or shooting pain. The prevalence of PDPN varies globally, with estimates suggesting that up to 26% of individuals with type 2 diabetes mellitus may experience neuropathic pain. The risk of developing PDPN increases with the duration of diabetes.
Description
Long-standing uncontrolled diabetes is a significant predictor of the development and progression of neuropathic symptoms. PDPN tends to be more prevalent in older individuals, and some studies indicate a slightly higher incidence in men than in women. Maintaining optimal glycemic control is paramount in preventing and managing PDPN. Poorly controlled diabetes significantly heightens the risk of neuropathic complications. Conditions such as obesity, dyslipidemia, and hypertension, which often coexist with type 2 diabetes mellitus, can exacerbate the risk of developing painful neuropathy. The consequences of PDPN extend beyond physical discomfort, profoundly affecting the overall quality of life for individuals with type 2 diabetes mellitus. PDPN can lead to a decline in mobility and daily functioning due to the persistent pain and discomfort, impacting activities such as walking and standing. Chronic pain associated with PDPN often leads to sleep disturbances, contributing to fatigue and exacerbating the emotional toll of the condition. Living with persistent pain can contribute to anxiety, depression, and decreased overall well-being. The emotional burden of PDPN is a critical aspect of its impact on individuals with type 2 diabetes mellitus. Maintaining optimal blood glucose levels is fundamental in preventing and managing PDPN. Strict adherence to diabetes management plans, including medications, lifestyle modifications, and regular monitoring, is crucial. Medications such as anticonvulsants, antidepressants, and certain analgesics may be prescribed to manage neuropathic pain. Individualized treatment plans are essential, considering factors such as comorbidities and medication tolerances. Incorporating regular physical activity, maintaining a healthy weight, and managing associated comorbidities contribute to overall well-being and can positively impact neuropathic symptoms. Collaboration with a multidisciplinary healthcare team, including endocrinologists, neurologists, and pain specialists, ensures comprehensive care addressing both the physical and psychological aspects of PDPN [1-4].
Conclusion
Painful diabetic peripheral neuropathy casts a long shadow over the lives of individuals with type 2 diabetes mellitus, underscoring the importance of proactive management and preventive measures. By addressing glycemic control, employing tailored pharmacological interventions, and embracing multidisciplinary approaches, healthcare professionals can strive to mitigate the impact of PDPN. Ongoing research and advancements in treatment options hold promise for further refining strategies to alleviate the burden of PDPN on individuals worldwide. In addition to traditional treatments, emerging therapeutic approaches offer hope for more targeted and effective management of PDPN in type 2 diabetes mellitus. Advancements in neuroprotective agents, regenerative medicine, and personalized medicine hold promise for tailoring interventions to individual patient profiles, addressing the heterogeneity of PDPN presentations.
Acknowledgement
None.
Conflict Of Interest
The author has nothing to disclose and also state no conflict of interest in the submission of this manuscript.
References
- Yorek MA. Is fish oil a potential treatment for diabetic peripheral neuropathy? Curr Diabetes Rev; 2018:14:339-349.
- Jarvis PRE. Euglycemic diabetic ketoacidosis: A potential pitfall for the emergency physician. Clin Exp Emerg Med; 2023:110-113.
- Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes Metab; 2022:2:101405.
- Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care; 2009:3:136-43.
